Share on StockTwits

Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost bought 20,000 shares of the stock on the open market in a transaction dated Friday, August 29th. The stock was purchased at an average cost of $8.91 per share, for a total transaction of $178,200.00. Following the transaction, the chief executive officer now directly owns 2,012,377 shares of the company’s stock, valued at approximately $17,930,279. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Jefferies Group reiterated a “buy” rating on shares of Opko Health in a research note on Wednesday, August 13th. They now have a $10.50 price target on the stock, down previously from $11.00. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $12.00.

Shares of Opko Health (NYSE:OPK) traded down 0.34% on Tuesday, hitting $8.87. 304,420 shares of the company’s stock traded hands. Opko Health has a 52 week low of $7.32 and a 52 week high of $12.95. The stock has a 50-day moving average of $8.94 and a 200-day moving average of $8.87. The company’s market cap is $3.807 billion.

Opko Health (NYSE:OPK) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.06) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.09) by $0.03. The company had revenue of $23.50 million for the quarter, compared to the consensus estimate of $23.70 million. During the same quarter last year, the company posted ($0.01) earnings per share. Opko Health’s revenue was down 1.3% compared to the same quarter last year. Analysts expect that Opko Health will post $-0.31 EPS for the current fiscal year.

OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.